Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T‐Cell Lymphoma
American Journal of Hematology · 2025
DOI: 10.1002/ajh.27736 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Alyssa Bouska und 43 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Immunoblastic Lymphadenopathy, Transcriptome, Lymphoma, T-Cell. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leukemia and Lymphoma Society, SCOR, NCI NIH HHS, Norges Forskningsråd.
Abstract (Originalsprache)
Nodal follicular helper T‐cell ( T FH ) lymphoma of the angioimmunoblastic (AITL) subtype has a dismal prognosis. Using whole‐exome sequencing ( n = 124), transcriptomic ( n = 78), and methylation ( n = 40) analysis, we identified recurrent mutations in known epigenetic drivers ( TET2, DNMT3A, IDH2 R172 ) and novel ones ( TET3, KMT2D ). TET2, IDH2 R172 , DNMT3A co‐mutated AITLs had poor prognosis ( p < 0.0001). Genes regulating T‐cell receptor (TCR) signaling ( CD28, PLCG1, VAV1 , FYN ) or activation ( RHOA G17V ) or regulators of the PI3K‐pathway (PIK(3)C members, PTEN, PHLPP1, PHLPP2 ) were mutated. CD28 mutation/fusion was associated with poor prognosis ( p = 0.02). WES of purified, neoplastic T‐cell (CD3 + PD1 + ) demonstrated high concordance with whole tumor biopsies and validated the presence of TET2 and DNMT3A in tumor and non‐lymphoid cells, but other mutations ( CD28 , RHOA G17V , IDH2 R172 , PLCG1 ) in neoplastic cells. Integrated DNA‐methylation and mRNA expression analysis revealed epigenetic alterations in genes regulating TCR, cytokines, PI3K‐signaling, and apoptosis. RNA‐seq analysis identified fusion transcripts regulating TCR‐activation (8%), revealed a restricted TCR‐repertoire (α = 87%, β = 72%), and showed the presence of Epstein–Barr virus transcriptome (73%). GEP demonstrated the association of B‐cells or dendritic cells in the tumor milieu with prognosis ( p < 0.01). RNA‐seq and WES analysis of 12 AITL‐patient‐derived‐xenografts (PDX) showed that bi‐allelic TET2 and DNMT3A mutations or sub‐clonal mutations ( PLCG1, PHLPP2 ) propagated in sequential passages, and gene signatures related to T FH and T CM (central‐memory) were well‐maintained through passages. Gene expression signatures associated with late PDX passages (3rd–5th) were enriched with proliferation and metabolic reprogramming‐related genes and predicted prognosis in an independent AITL series. Low PHLPP2 mRNA expression predicted poor prognosis ( p = 0.05) and engineered PHLPP2 or TET2 loss in CD4 + T‐cells showed enhanced PI(3)K activation, thus uncovering a therapeutic target for clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Department of Oncology, Oslo University Hospital, Oslo, Norway.
- KG Jebsen Centre for B-Cell Malignancies, Oslo, Norway.
- Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
- Department of Pathology and Laboratory Medicine, Weil Cornell Medical College, New York, New York, USA.
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Alyssa Bouska, Waseem G Lone, Luca Vincenzo Cappelli, Choon Kiat Ong, David Weinstock
Förderung
- Leukemia and Lymphoma Society, SCOR
- NCI NIH HHS
- Norges Forskningsråd
- National Cancer Institute
- Leukemia and Lymphoma Society
Zitieren
APA
Bouska, A., Zhang, W., Sharma, S., Holte, H., Shah, R. A., Lone, W. G., Soma, M. A., Yang, R., Liu, X., Mehmood, S., Chawla, R. S., Cappelli, L. V., Fiore, D., Gong, Q., Heavican-Foral, T. B., Cannatella, J. J., Amador, C., Arif, A., Smith, L. M., …, & Iqbal, J. (2025). Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T‐Cell Lymphoma. American Journal of Hematology. https://doi.org/10.1002/ajh.27736
Vancouver
Bouska A, Zhang W, Sharma S, Holte H, Shah RA, Lone WG, et al. Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T‐Cell Lymphoma. American Journal of Hematology. 2025. doi:10.1002/ajh.27736
BibTeX
@article{Bouska2025,
author = {Bouska, Alyssa and Zhang, Weiwei and Sharma, Sunandini and Holte, Harald and Shah, Rauf A and Lone, Waseem G and Soma, Mahfuza Afroz and Yang, Ruimeng and Liu, Xuxiang and Mehmood, Syed and Chawla, Ravneet Singh and Cappelli, Luca Vincenzo and Fiore, Danilo and Gong, Qiang and Heavican-Foral, Tayla B and Cannatella, Jeffrey J and Amador, Catalina and Arif, Aiza and Smith, Lynette M and Lim, Soon Thye and Ong, Choon Kiat and Feldman, Andrew L and Du, Ming-Qing and Perry, Anamarija M and de Leval, Laurence and Greiner, Timothy C and Fu, Kai and Trøen, Gunhild and Vodák, Daniel and Nakken, Sigve and Delabie, Jan and Weinstock, David and Pileri, Stefano and Laginestra, Antonella and Kim, KyeongJin and Pajvani, Utpal and Vose, Julie M and Weisenburger, Dennis D and Horwitz, Steven M and Dave, Sandeep and Khoury, Joseph and Inghirami, Giorgio and Chan, Wing C and Iqbal, Javeed},
title = {Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T‐Cell Lymphoma},
journal = {American Journal of Hematology},
year = {2025},
doi = {10.1002/ajh.27736}
}
EUVIMED